

# Endothelial Nitric Oxide Synthase (Enos) 4b/A Gene Polymorphism And The Risk Of Diabetic Nephropathy In Type 2 Diabetes

lectur. Lamees M.Al-Janabi

[lamees-m@utq.edu.iq](mailto:lamees-m@utq.edu.iq)

Asst. Prof. Dr. Abdul Hussain A. Algenabi

lectur. Ahmed J. Mohammed

## Abstract

Diabetic Nephropathy (DN) poses a major health problem. There is strong evidence for a potential role of the eNOS gene. The aim of this case control study was to investigate the possible role of genetic variants of the endothelial Nitric Oxide Synthase (eNOS) gene(VNTR) in the pathogenesis of nephropathy in patients with diabetes mellitus. The study included 196 subjects (145 T2DM and 51 normal control) T2DM were classified into 2 groups: 97 diagnosed with DN, and 48 diabetic without nephropathy and hypertension as +ve control. randomly selected was conducted to assess the association of SNP eNOS intron 4a/b VNTR polymorphism gene with diabetic nephropathy in Iraqi population. Blood samples from subjects and controls were analyzed to investigate the eNOS genotypes No significant differences were found in the frequency of eNOS genotypes between diabetic patients (either in group 1 or group 2) and controls ( $p > 0.05$ ). Also, no significant differences were found in the frequency of eNOS genotypes between group 1 and group 2 ( $p > 0.05$ ).

## Introduction

Diabetes is among the major causes of renal failure. 10-20% of fatalities in diabetic patients are related to renal failure<sup>(1)</sup>. Type II diabetes and diabetic nephropathy are obviously chronic progressive disorders that are related to a group of genetic, lifestyle and environmental factors<sup>(2)</sup>.

The exact etiology is unknown, but hyperglycemia and high blood pressure are considered to contribute to diabetic nephropathy. Persistently high blood sugar or blood pressure levels are two factors that can damage the kidneys, making them incapable of filtering

wastes and remove water from your body<sup>(3)</sup>.

It is a major cause of end-stage renal disease. There are glomerular hemodynamic derangements leading to glomerular hyper-filtration, causing glomerular damage as indexed by microalbuminuria. There is overt proteinuria, decreased glomerular filtration rate, and end-stage renal failure<sup>(4)</sup>.

NO is a vasodilator molecule produced from its precursor L-arginine by a family of NO synthases (NOSs)<sup>(5)</sup>. The NO system is formed of three distinct NO synthase (NOS) isoforms,


encoded by three distinct genes, including neuronal (nNOS or NOS-1), inducible (iNOS or NOS-2) and endothelial (eNOS or NOS-3). The gene encoding eNOS is found on chromosome 7 (7q35-q36) and contains 26 exons with an entire length of 21 kb (6,7).

NO takes part in control functions including regulation of hemostasis, fibrinolysis, platelet and leukocyte inter play with the arterial wall, vasculature control, vascular smooth muscle cell proliferation and blood pressure regulatory mechanisms.

Imbalance in NO bioavailability have been shown to result in endothelial dysfunction, causing increased liability to atherosclerotic lesion progression, hypertension, hypercholesterolemia, diabetes mellitus, thrombosis and stroke<sup>(8,9)</sup>.

The eNOS gene has been thought of as a possible candidate gene to DN liability. The presence of eNOS polymorphisms might contribute to a decreased eNOS activity and a reduced NO level, and has been reported to be a potential factor in the pathogenesis and development of DN. This polymorphism consists of the two alleles of eNOS 4a with 4 tandem 27-repeats and eNOS 4b with 5 repeats<sup>(10)</sup>.

The eNOS gene has 2 common alleles including 4 repeats (a) and 5 repeats (b) which form 2 homozygous (aa and bb) and 1 heterozygous (ab) genotypes<sup>(11)</sup>. Recently, the eNOS intron 4a/b VNTR polymorphism has been shown to be related to changed plasma NO levels and responsible for alterations in the genetic regulation of blood nitrite and nitrate concentration and enzyme formation<sup>(12,13)</sup>.



**Figure 1 :Location of eNOS intron 4a/b VNTR gene in chromosome 7q3536<sup>(14)</sup>**

## Research Design and Methods

A case-control study of 196 subjects (145 T2DM and 51 normal control) T2DM were classified into 2 groups: 97 diagnosed with DN, and 48 diabetic without nephropathy and hypertension as +ve control. randomly selected was conducted to assess the association of SNP eNOS intron 4a/b VNTR polymorphism gene with diabetic nephropathy in Iraqi population.

### Inclusion criteria:

1. Those patients who were diagnosed by physicians as having type 2 diabetes, the criteria to diagnose diabetes were based on WHO guidelines.
2. A subject is said to have diabetes if his/her fasting glucose level was >126 mg/dl (7.0 mmol/l) +symptoms of diabetes (polyuria, nocturia, polyphagia and weight loss).
3. Albuminuria (>300 mg/24 h or >200 µg/min or >200 mg/L) in

two of three consecutive measurements on sterile urine samples—with or without renal failure (serum creatinine >150 µmol/L).

4. Albumin/creatinine ratio > 2.5
5. Age of patients was >40 years old.

#### Exclusion criteria.

1. Those diagnosed with T1DM.
2. congestive heart failure.
3. chronic kidney disease.
4. urinary tract infection.
5. Hematuria.
6. acute febrile illness.

#### Laboratory analysis

Five milliliters of blood were taken from all subjects collected in two tubes, 2.5 ml in plain tube without anticoagulants and 2.5 ml in EDTA tube. After that, the serum tube centrifuged at 2000 xg for approximately 10 minutes, the sera were aspirated and divided into two aliquots, and stored at (-20 °C) until time of use. The EDTA tube was used for extraction of DNA.

#### DNA extraction

Peripheral blood samples of patient and control groups were collected in EDTA tubes, and then DNA was extracted from whole-blood samples using Genomic DNA Mini Kit (Blood / cultured cell) (Geneaid) <sup>(15)</sup>.

The eNOS gene intron 4, 27 bp VNTR polymorphism was detected by polymerase chain reaction (PCR) according to the method described by Shah *et al* <sup>(237)</sup>. The template DNA (0.5 µg per sample) was amplified

using the following primers: (forward) 5'-AGG CCC TAT GGT AGT GCC TTT-3' and 5'-TCT CTT AGT GCT GTG CTC AC-3' (reverse). These primers (10 pmol of each) were added to a mixture containing 0.2 µmol/L each of dATP, dCTP, dGTP, and dTTP; 5 µL of 10× Cetus buffer (pH 8.3); 5 µL of DMSO (100%); and 0.5 units of Taq DNA Polymerase (Perkin Elmer Cetus), in a final volume of 20 µL.

The PCR was initiated with a denaturation by first heating the samples for 5 min at 94 °C. Thirty-five cycles of denaturation for 1 min at 94 °C, annealing for 1 min at 56 °C, primer extension for 2 min at 72 °C, and a last extension for 5 min at 72 °C were applied for amplification. The PCR products of the NO gene locus were examined by gel electrophoresis (2% NuSieve agarose-agarose) at 75 V for 120 min and visualized at room temperature under UV light after ethidium bromide staining.

#### Statistical analysis

Continuous variables expressed as mean ±SD and Student's t-test was used to determine differences in means between control and T2DM groups. ANOVA test and Student's t-test was used to compare mean levels of continuous characteristics across genotypes using SPSS v. 20.0 software (SPSS Inc., Chicago, IL). Categorical data (genotypes and alleles) were expressed as frequency. In all statistical analysis the level of significance was <0.05.

Hardy-Weinberg equilibrium (HWE) is a mathematical relationship

that related genotypes to allele frequencies<sup>(16)</sup>. Genetic power was calculated using the online software

OSSE {online sample size estimator} ([osse.bii.a-star.edu.sg](http://osse.bii.a-star.edu.sg))<sup>(17)</sup>.

## Results

### Age

The diabetic and control groups were found to be matched in age. The distribution of age among the two groups was shown in figure 2.




Figure 2: Age distribution of study subjects

### Gender

The diabetic and control groups were found to be matched in gender. The distribution of gender among the two groups was shown in figure 3.





Figure3: Gender distribution of study subjects

### Results of amplification reactions

The amplification product of eNOS(VNTR) gene polymorphism i.e, the 4a/4b as described by Shah *et al.*<sup>(18)</sup> . Results were confirmed by agarose gel electrophoresis (figure 4 ).




**Figure 4: PCR product of DNA analyzed by agarose gel electrophoresis.**

DNA was extracted from blood, The PCR product was electrophoresed on 2% agarose (75V and 120 min.) and directly visualized with ethidium bromide under UV light.

The PCR product of eNOS gene polymorphism were analyzed by agarose gel electrophoresis. Results demonstrated one ( 420 bp), one (393 bp) and two ( 420 , 393 bp) bands for those with wild type (bb), homozygous (aa) and heterozygous (ab) genotypes respectively (figure 5).

The overall power of the current study to detect a significant difference at level of 0.05 was estimated and found to be 79.9 % for eNOS(VNTR) gene polymorphism. Genotype frequencies of eNOS(VNTR) were deviated from Hardy–Weinberg equilibrium in T2DM and control subjects( $P < 0.05$ ).



**Figure 3.9. Results of eNOS gene polymorphism product on agarose gel electrophoresis.** PCR product of eNOS gene were electrophoresed on 3% agarose (75V and 120 min) and directly visualized with ethidium bromide under UV light.

Lines: DNA Marker  
 Lines 1, 3, 4,7,10 : ab genotype 420,390 bp  
 Lines 2, 5,6 :aa genotype 390 bp  
 Lines 8,9 :bb genotype 420 bp

## Genotype and allele frequencies

To determine the genotyping error rate, a random duplication in 10% of the samples was reanalyzed. The concordance was obtained to be 100%. The genotype and allele frequencies of eNOS gene polymorphism in T2DM with nephropathy and normal control subjects in codominant, dominant and

recessive models were examined by multinomial logistic regression analysis.

The genotype and allele frequencies of eNOS(VNTR) gene polymorphism in DN stated no significance association of DN with both normal control and diabetic control without nephropathy(table 1 and 2) respectively.

**Table 1: Results of genotype and allele frequency of eNOS gene polymorphism in patient and normal control groups**

eNOS (a/b)	Control -ve n=51	DN n=97	Unadjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
<b>Codominant</b>						
bb(Reference)	19	16				
Ab	18	56	0.53 (0.2 -1.2)	0.13	0.53 (0.2 - 1.2)	0.14
Aa	13	25	1.3 (0.5 - 3.3)	0.57	1.68 (0.6 – 4.4)	0.29
<b>Dominant</b>						
aa+ab(Reference)	17	40	0.7 (0.3- 1.5)	0.5	0.8 (0.3 -1.4)	0.4
<b>Recessive</b>						
ab+bb(Reference)	41	75				
Aa	10	22	1.2 (0.5- 2.7)	0.6	1.1 (0.4- 2.6)	0.7
Frequency of a allele	36 35.2%	60 30.9%	0.8 (0.5- 1.4)	0.6		

**Table 2: Results of genotype and allele frequency of eNOS gene polymorphism in patient and +ve control groups.**

eNOS (a/b)	Control +ve n=48	DN n=97	Unadjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
Codominant						
bb(Reference)	10	16				
Ab	28	56	0.54 (0.23- 1.25)	0.15	0.75 (0.3- 1.8)	0.52
Aa	10	25	1.25 (0.49- 3.18)	0.63	2.63 (0.8- 7.9)	0.08
Dominant						
aa + ab	23	40	0.7 (0.3- 1.5)	0.5	0.6 (0.3- 1.4)	0.3
Recessive						
ab + bb	41	75				
aa	7	22	1.7 (0.6- 4.3)	0.2	1.5 (0.6- 4.2)	0.3
Frequency of a allele	29 30.2%	60 30.9%	0.08 (0.6- 1.8)	0.7		

**Table 3: The distribution of the eNOS genotypes**

	bb	ab	aa
Cases N=97	58.7%(57)	18.5%(18)	21.6%(21)
Control N=51	49%(25)	31.3%(16)	19.6%(10)

## Discussion

### SNPs of eNOS(VNTR) genes in patients and control group

Why some diabetic patients develop nephropathy, whereas others do not, despite having a long-term hyperglycemia, remains an unresolved problem. Because known environmental factors do not fully explain this, researchers have sought the answer at the genetic background of the host.

In our study the eNOS gene bb is the most frequent allele which present in 57.9%, followed by aa then ab (21.6% and 18.5%) respectively. While Neugebauer et al<sup>(19)</sup> the frequency of bb, ab, and aa genotypes in patients are 69.2%, 23.0% and 8%, respectively. In cocasian populations the frequency of bb, ab, and aa genotypes are 72.1%, 26.9%, and 1% respectively<sup>(20)</sup>.



However, genotype frequencies of eNOS gene were deviated from Hardy–Weinberg equilibrium in control persons and DN subjects ( $P=0.000$ ). Previously, Ksiasek et al.<sup>(21)</sup> have reported such observation but others<sup>(22, 20)</sup> have confirmed consistence with HWE. The deviation from HWE may be attributed to the small sample size of our study<sup>(23)</sup>.

The calculated genetic power to detect a significant difference at level of 0.05 for eNOS was 79.9% respectively, which is seemed to be greater than the optimal level (80%). The MAF of eNOS in the normal control group (35.2%) while in the diabetic control (30.2%) which higher than Japanese population (7.1%,7.3%) respectively<sup>(19)</sup>, and Poland people (0.14%)<sup>(24)</sup>. Germany<sup>(20)</sup>, Tunisia (23.24%)<sup>(22)</sup>, East-Asian (India) (13.9%)<sup>(25)</sup>.

Results of eNOS gene polymorphism did not reveal significant difference in the distributions among patients and the

control group these results are consistent with studies of Egyptian<sup>(26)</sup>, East Asian<sup>(22)</sup>, Chinese<sup>(27)</sup>, Iranian<sup>(28)</sup>, Japanese population<sup>(29)</sup>.

Although there is evident association of eNOS (VNTR) gene polymorphism with DN in other studies<sup>(5,19,22,25,26)</sup>. the current investigation did not reveal such observation. Here, it is beneficial to suggest the possibility of other variants of eNOS gene to be involved in the development of the disease. Most of the studies on the 4b/a variants function reveal a minimal difference between each genotype. This is perhaps due to the non-coding location of this polymorphism. However, there is also a report which suggested that this variant contributes to basal levels of plasma NO<sup>(12)</sup>. Thus, we cannot exclude the possibility of 4b/a variable number of tandem repeats as a functional significant factor to DN risk.

## References

1. Rambhade S., Chakraborty A. K., Patil U. K., et al. Diabetes Mellitus- Its complications, factors influencing complications and prevention- An Overview. J. Chem. Pharm. Res., 2010, 2(6):7-25.
2. Phillip MH. Prevention of Progression in Diabetic Nephropathy Diabetes Spectrum. 2006; 19(1): 18-24.
3. Forbes J M, Fukami K, Cooper M E. Diabetic Nephropathy: Where Hemodynamics Meets Metabolism. Exp Clin Endocrinol Diabetes 2007; 00:1 – 16.
4. Edmund JL Xiulong, X . Abnormal glomerular permeability characteristics in diabetic nephropathy: Implication for the therapeutic use of the low- molecular weight heparin Diabetes Care. 2008; 31(2): S202–S207.
5. Dellamea B S, Ferreira Pinto L C, Leitão C B, et al. Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis. BMC Medical Genetics. 2014, 15:9 .



6. Bredt DS, Snyder SH: Nitric oxide: a physiologic messenger molecule. *Annu Rev Biochem* 1994, 63:175–195.
7. Tsutsui M, et al: Nitric oxide synthases and cardiovascular diseases: insights from genetically modified mice. *Circ J* 2009, 73(6):986–993.
8. Napoli C, Ignarro LJ: Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. *Arch Pharm Res* 2009, 32(8):1103–1108.
9. Huang PL: eNOS, metabolic syndrome and cardiovascular disease. *Trends Endocrinol Metab* .2009;20(6):295–302.
10. MA Z, Chen R, Ren H, et al. Endothelial nitric oxide synthase (eNOS) 4b/a polymorphism and the risk of diabetic nephropathy in type 2 diabetes mellitus: A meta-analysis. *Meta Gene* . (2014);2: 50–62.
11. Yoon Y, Song J, Hong SH, Kim JQ. Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. *Clin Chem* .2000; 46: 1626-30.
12. Wang XL, Mahaney MC, Sim AS, et al. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. *Arterioscler Thromb Vasc Biol* .1997; 17: 3147-53.
13. Bolli P, Sticchi E, Abbate R, et al . A novel allele of eNOS gene in the Italian population: the actual essence of intron 4 polymorphism. *Nitric Oxide*. 2007; 16: 392-4.
14. [www.genecards.org](http://www.genecards.org).
15. Volgelstein, B., and Gillespie, D.(1979) *Pro. Natl. Acad. Sci. USA* 76.
16. Thompson, Margaret W., Roderick R. McInnes, and Huntington F. Willard. 1991. *Thompson & Thompson genetics in medicine*. Fifth ed. Philadelphia: W. B. Saunders.
17. [osse.bii.a-star.edu.sg](http://osse.bii.a-star.edu.sg).
18. Shah V N, Cheema B S, Kohli H S, et al. Endothelial Nitric Oxide Synthase Gene polymorphism and the risk of diabetic Neuropathy in Asian Indian Patients with Type 2 Diabetes. 2013. *J Diabetes Metab*. 4.2.
19. Neugebauer S, Baba T, and Watanabe T. Association of the Nitric Oxide Synthase Gene Polymorphism With an Increased Risk for Progression to Diabetic Nephropathy in Type 2 Diabetes. *Diabetes*. 2000; 49 :500–5030.
20. Bernhard Degen, Susanne Schmidt, Eberhard Ritz. A polymorphism in the gene for the endothelial nitric oxide synthase and diabetic nephropathy. *Nephro Dia Transplant* .2001.16:185-198.
21. Ksiazek P, et al: Endothelial nitric oxide synthase gene intron 4 polymorphism in type 2 diabetes mellitus. *Mol Diagn* 2003, 7(2):119–123.
22. Ezzidi I, Mtiraoui N, Mohamed MBH, et al. Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786 T > C gene variants with diabetic nephropathy. *J Diabetes Complications*. 2008; 22(5):331–338.
23. Elias Zintzaras Impact of Hardy-Weinberg equilibrium deviation on allelebased risk effect of genetic association studies and meta-analyses, *European Journal of Epidemiology* 25, 8 (2010) 553-560.

24. Buraczynska M, Ksiazek P, Zaluska W, et al. Endothelial nitric oxide synthase gene intron 4 polymorphism in patients with end-stage renal disease. *Nephrol Dial Transplant* (2004) 19: 2302–2306.
25. Ahluwalia, T. S., Ahuja, M., Rai, T. S., Kohli, H. S., Sud, K., Bhansali, A. and Khullar, M. Endothelial nitric oxide synthase gene haplotypes and diabetic nephropathy among Asian Indians. *Mol. Cell Biochem.* 2008;314, 9–17.
26. Shoukry A, Shalaby S M, Abdelazim S, et al. Endothelial Nitric Oxide Synthase Gene Polymorphisms and the Risk of Diabetic Nephropathy in Type 2 Diabetes Mellitus. *Genetic Testing and Molecular Biomarkers*. 2012;16(6): 574–579.
27. Lin S, Qu H, Qiu M. Allele A in intron 4 of eNOS gene will not increase the risk of DN in type 2 diabetes of Chinese population. *Nephron*. 2002; 91:768.
28. Rahimi, Z., Rahimi, Z., Shahvaisy-Zadeh, F., Sadeghei, S., Vessal, M., Yavari, N., 2013. eNOS 4a/b polymorphism and its interaction with eNOS G894T variants in type 2 diabetes mellitus: modifying the risk of diabetic nephropathy. *Dis. Markers*. 2013; 34, 437–443.
29. Taniwaki H, Ishimura E, Matsumoto N, et al. Relations Between ACE Gene and eNOS Gene Polymorphisms and Resistive Index in Type 2 Diabetic Patients With Nephropathy. *Diabetes Care*. 2001;24:1653–1660.

## علاقة اوكسيد النتريك جين (VNTR) مع خطر اعتلال الكلية السكري

### عند مرضى السكري نوع ٢

م. احمد جلال محمد

أ.م.د. عبدالحسين الجنابي

م.د. لميس ماجد الجنابي

#### الخلاصة:

اعتلال الكلية السكري (DN) يشكل مشكلة صحية كبيرة. هناك أدلة قوية على وجود دور محتمل للجين VNTR. وكان الهدف من هذه الدراسة السيطرة القضية إلى التحقيق في دور محتمل من المتغيرات الجينية من بطانة اكسيد النتريك سينسيز الجين (VNTR) في التسبب في اعتلال الكلية في المرضى الذين يعانون من داء السكري. وشملت الدراسة ١٩٦ شخصا T2DM 145 و ٥١ الضابط تم تصنيف T2DM إلى مجموعات ٢: ٩٧ مصابين DN، و ٤٨ مريض السكر دون اعتلال الكلية وارتفاع ضغط الدم. تم اختيارها عشوائيا أجريت لتقييم جمعية SNP إنترون 4b / 4a VNTR تعدد الأشكال الجيني مع اعتلال الكلية السكري في الشعب العراقي. وقد تم تحليل عينات الدم من الموضوعات والضوابط للتحقيق في المورثات. لم يتم العثور على اختلافات كبيرة في وتيرة الأنماط الجينية VNTR بين مرضى السكري (إما في مجموعة 1 أو المجموعة ٢) والضوابط ( $P > 0.05$ ). أيضا، لا توجد اختلافات كبيرة في وتيرة VNTR الأنماط الجينية بين مجموعة 1 والمجموعة ٢ ( $P > 0.05$ ).